Associated Papers
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.
Mu Y et al.
Thoracic Cancer, 2023
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
35468810 (PubMed )
Supplement: 12920_2022_1235_MOESM3_ESM.xlsx › OncoKB_unspecified-alterations.
Prevalence and role of HER2 mutations in cancer.
Cocco E et al.
Pharmacology & Therapeutics, 2019
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
31034466 (PubMed )
Supplement: pcbi.1006981.s010.xlsx › final_benchmark
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
30736836 (PubMed )
Supplement: 13058_2019_1102_MOESM2_ESM.xlsx › Sheet1
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacological Research, 2019
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Zabransky DJ et al.
Proceedings of the National Academy of Sciences of the United States of America, 2015
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.
Ng CK et al.
Genome Biology, 2015
The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacological Research, 2014
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R et al.
Cancer Discovery, 2013
Select a paper to view details